Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02902757 · ClinicalTrials.gov registry record · NA
FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma
A NA study, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT02902757 is a NA study that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 7 participants.
The verdict
NCT02902757, a NA study, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
This pilot clinical trial studies fluordeoxyglucose (fludeoxyglucose) F-18 (FDG) positron emission tomography (PET)/computed tomography (CT) in monitoring very early therapy response in patients with glioblastoma. Diagnostic procedures, such as FDG PET/CT, may help measure a patient's response to earlier treatment. Chemotherapy can induce very rapid changes to the tumor's glucose consumption which can be measured with imaging. FDG PET/CT shortly after the start of therapy may help identify very early therapy response in patients with glioblastoma.
Interventions
- PROCEDURE Computed Tomography
- PROCEDURE Positron Emission Tomography
- RADIATION Fludeoxyglucose F-18
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2015-08-25 |
| Est. Completion | 2025-01-29 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02902757
The ClinicalTrials.gov registry entry for NCT02902757 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Computed Tomography is the first listed.
NCT02902757 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02902757 about?
NCT02902757 is a clinical study titled "FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma". This pilot clinical trial studies fluordeoxyglucose (fludeoxyglucose) F-18 (FDG) positron emission tomography (PET)/computed tomography (CT) in monitoring very early therapy response in patients with glioblastoma. Diagnostic procedures, such as FDG PET/CT, may help measure a patient's response to ea...
What is the current status of trial NCT02902757?
This trial is currently completed. It is a NA study. The enrollment target is 7 participants. The study started on 2015-08-25. Estimated completion is 2025-01-29.
What interventions are being tested in trial NCT02902757?
The interventions under investigation include: Computed Tomography (PROCEDURE), Positron Emission Tomography (PROCEDURE), Fludeoxyglucose F-18 (RADIATION).
Who is sponsoring clinical trial NCT02902757?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.